HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Poseida Therapeutics, maintaining a $20 price target.
October 30, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Poseida Therapeutics, maintaining a $20 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $20 price target by HC Wainwright & Co. suggests a positive outlook for Poseida Therapeutics. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100